Cemiplimab Combo Does Not Show Superior ORR to Anti-PD-1 Monotherapy in Advanced HNSCC - Targeted Oncology

Cemiplimab Combo Does Not Show Superior ORR to Anti-PD-1 Monotherapy in Advanced HNSCC  Targeted Oncology

The PD-1 inhibitor cemiplimab in combination with radiotherapy, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor did not demonstrate ...

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Bgn7iy